Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILGEN anti-LAG-3 antibody
- Development stage
- Preclinical
- Lead developer
- ILGEN
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
ILGEN's anti-LAG-3 antibody is a fully human monoclonal antibody currently in preclinical development for the treatment of various cancers. It targets Lymphocyte Activation Gene-3 (LAG-3), an inhibitory checkpoint receptor expressed on the surface of activated T cells. By blocking the interaction between LAG-3 and its ligands, the antibody relieves immune suppression and enhances the antineoplastic activity of the immune system. The candidate was developed using ILGEN's proprietary technology platform (US Patent 9810694) for generating high-affinity, fully human antibodies and has been featured in research presentations at ESMO and AACR.
- Other names
- anti-LAG-3 monoclonal antibodyanti-LAG3 monoclonal antibodyanti-LAG 3 monoclonal antibodyfully human anti-LAG-3 antibody
02
Targets
LAG3 (Lymphocyte activation Gene-3 protein)
Beyond the preview
Go deeper on ILGEN anti-LAG-3 antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILGEN anti-LAG-3 antibody.